Zeo ScientifiX, Inc. (ZEOX): Operating Cash Flow
-$718.0K
Year ended 2025-10-31
-$1.25M
Trailing 12 months to 2026-04-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-10-31 | -$718.0K | n/m | 2026-01-29, From 2024-11-01 |
| 2024-10-31 | -$1.45M | n/m | 2026-01-29, From 2023-11-01 |
| 2023-10-31 | -$2.20M | n/m | 2025-01-29, From 2022-11-01 |
| 2022-10-31 | -$3.17M | n/m | 2024-01-29, From 2021-11-01 |
| 2021-10-31 | -$2.68M | n/c | 2023-02-14, From 2020-11-01 |
| 2020-10-31 | -$1.81M | n/m | 2022-02-14, From 2019-11-01 |
| 2019-10-31 | -$565.5K | n/m | 2021-02-08, From 2018-11-01 |
| 2018-10-31 | -$512.0K | n/m | 2020-10-16, From 2017-11-01 |
| 2017-10-31 | -$881.5K | n/m | 2020-03-06, From 2016-11-01 |
| 2016-10-31 | -$548.2K | n/m | 2018-11-01, From 2015-11-01 |
| 2015-10-31 | -$446.5K | n/c | 2017-07-07, From 2014-11-01 |
| 2014-10-31 | -$62.5K | n/c | 2016-06-22, From 2013-11-01 |
| 2013-10-31 | -$30.0K | n/m | 2015-02-17, From 2012-11-01 |
| 2012-10-31 | -$8.7K | n/m | 2014-03-11, From 2011-11-01 |
| 2011-10-31 | -$12.9K | n/a | 2013-02-13, From 2010-11-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | -$718.0K | n/m |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | -$121.18M | n/m |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | -$162.56M | n/m |
| Ocugen, Inc. (OCGN) | 2025-12-31 | -$56.96M | n/m |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | -$106.08M | n/m |
| CG Oncology, Inc. (CGON) | 2025-12-31 | -$132.35M | n/m |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | -$345.01M | n/m |
| Surrozen, Inc. (SRZN) | 2025-12-31 | -$30.24M | n/m |
| Dyadic International Inc (DYAI) | 2025-12-31 | -$5.70M | n/m |
Compare ZEOX, DBVT, PRME, OCGN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗